We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

18 hedge funds and large institutions have $932K invested in Theriva Biologics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.05% → 0.04% (-0.01%)

14% less funds holding

Funds holding: 21 → 18 (-3)

28% less capital invested

Capital invested by funds: $1.3M → $932K (-$365K)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

Holders
18
Holders Change
-3
Holders Change %
-14.29%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
5
Closed
5
Calls
$2.87M
Puts
–
Net Calls
+$2.87M
Net Calls Change
-$674K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$126K
2
WS
Wedbush Securities
California
+$56.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$20K
4
SPIA
Steward Partners Investment Advisory
New York
+$144

Top Sellers

Rank Fund Capital Flow
1
TS
Third Security
Virginia
-$256K
2
VF
Virtu Financial
New York
-$64K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$22.4K
4
Citadel Advisors
Citadel Advisors
Florida
-$17K
5
TSS
Two Sigma Securities
New York
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$497K +$126K +875 +32%
Renaissance Technologies
2
Renaissance Technologies
New York
$240K +$20K +139 +9%
WS
3
Wedbush Securities
California
$54K +$56.4K +392 New
BFM
4
Boothbay Fund Management
New York
$33K – – –
William Blair & Company
5
William Blair & Company
Illinois
$30K -$1.44K -10 -4%
6CM
6
683 Capital Management
New York
$24K – – –
BlackRock
7
BlackRock
New York
$21K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$10K -$22.4K -156 -68%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$9K – – –
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$6K -$1.29K -9 -18%
Goldman Sachs
11
Goldman Sachs
New York
$6K – – –
LTFS
12
Ladenburg Thalmann Financial Services
Florida
$2K – – –
BNP Paribas Financial Markets
13
BNP Paribas Financial Markets
France
$1 – – –
TS
14
Third Security
Virginia
– -$256K -1,513 Closed
VF
15
Virtu Financial
New York
– -$64K -376 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$17K -102 Closed
TSS
17
Two Sigma Securities
New York
– -$13K -75 Closed
FIA
18
FNY Investment Advisers
New York
– -$4K -28 Closed
UBS Group
19
UBS Group
Switzerland
– -$2.01K -14 -88%
Morgan Stanley
20
Morgan Stanley
New York
– -$144 -1 -50%
SPIA
21
Steward Partners Investment Advisory
New York
– +$144 +1 New

TOVX Hedge Fund Activity: Q2 2019 in Review

18 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2019, worth a combined $932K — down 28% from $1.3M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TOVX and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, adding an estimated $126K. The largest seller was Third Security, exiting entirely with an estimated $256K sold.

  • 18 institutional investors held Theriva Biologics (TOVX) as of Q2 2019, down from 21 in Q1 2019.
  • Funds reported $932K of Theriva Biologics stock for Q2 2019, down 28% quarter-over-quarter.
  • 2 funds opened new Theriva Biologics positions in Q2 2019 and 5 closed out, a net change of -3 holders.
  • The largest Theriva Biologics buyer in Q2 2019 was Sabby Management, an estimated $126K added.
  • The largest Theriva Biologics seller in Q2 2019 was Third Security, an estimated $256K sold.

Based on aggregated 13F filings for Q2 2019.